| Typicality: | 0.229 |
| Saliency: | 0.331 |
| with trastuzumab | 4 | other |
| for life expectancy | 3 | other |
| evidence → be provided by → the company | 12 |
| evidence → be submitted by → the company | 6 |
| evidence → be produced by → the company | 4 |
| evidence → be presented by → the company | 4 |
| negative | neutral | positive |
| 0.159 | 0.738 | 0.103 |
| Raw frequency | 26 |
| Normalized frequency | 0.331 |
| Modifier score | 0.000 |
| Perplexity | 84.635 |